April 10th, 2012
Selections from Richard Lehman’s Literature Review: Week of April 10th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the EINSTEIN-PE trial of rivaroxaban, the risk for suicide or cardiovascular death after cancer diagnosis, and a comparison of computer reminders vs. pharmacist outreach about medication dangers.
April 4th, 2012
Suicide and CV Death Increase After Cancer Diagnosis
Larry Husten, PHD
The risks for suicide and cardiovascular death rise sharply after cancer is diagnosed, according to a new study from Sweden published in the New England Journal of Medicine. Fang Fang and colleagues analyzed data from more than 6 million Swedes, including more than half a million who received a first diagnosis of cancer. Following sharp initial increases in […]
August 12th, 2010
CRESCENDO: The Fat Lady Sings for Rimonabant
Larry Husten, PHD
The CRESCENDO (Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes) trial, which tested the effects of the endocannabinoid receptor blocker rimonabant for the prevention of cardiovascular events, was terminated early at the request of regulatory agencies in several countries following growing concern that people taking rimonabant were more likely to commit suicide. At the […]
NEJM Journal Watch — Recent Cardiology Articles- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise